FDA Approves Updated Label for Unloxcyt

WEDNESDAY, Dec. 3, 2025-- The U.S. Food and Drug Administration has approved an updated label for Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not...